ImageneBio, Inc. (IMA): Nasdaq/NYSE listing notice — Ikena Oncology self-reports Nasdaq rule violation; remediated via share repurchase

ImageneBio, Inc.

Issued 6,110,000 shares at $6.55 in May 2023 offering, inadvertently exceeding 20% threshold of pre-transaction voting shares.
Repurchased 97,500 shares from an investor to remediate the excess issuance and self-reported to Nasdaq.
Nasdaq determined compliance with Listing Rule 5635(d) is regained; matter closed with no effect on listing of IKNA common stock.
Company remains listed on The Nasdaq Global Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ImageneBio, Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5635(d)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: shareholders
Rules: 5635(d)

Exact text from the filing

June 30, 2023, Ikena Oncology, Inc., a Delaware corporation (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in response to a self-reported discovery and resolution of non-compliance with Listing Rule 5635(d). The letter notified the Company of the Staff’s determination that the Company had failed to comply with Listing Rule 5635(d), as well as the Staff’s determination that the Company had remediated the deficiency and regained compliance with Listing Rule 5635(d), and the matter is now closed, as further desc

View on SEC.gov

Browse all listing & compliance notices →

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-180591

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.